Seagen Deal History & Licensing Activity
Seagen is a large biotech headquartered in US. Over the past three years, Seagen has been involved in 4 licensing and acquisition transactions, with a primary focus on ADC (3 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
1
Active Trials
50
Top Modality
ADC
Focus Area
Solid Tumors
Seagen Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Seagen in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Anti-Orexin-101 | Passage Bio | ADC | Phase 3 | acquisition | Dec 2025 |
Seagen Pipeline Focus
Therapeutic areas and modalities where Seagen is most active based on deal history and clinical trial data.
Seagen Strategic Signals
Key indicators of Seagen's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Seagen Clinical Pipeline
Seagen has 50 active clinical trials across 4 development phases.
1
Unknown
13
Phase 1
25
Phase 2
11
Phase 3
See How Your Asset Matches Seagen's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Adc Her2 Benchmarks
Upfront, milestone, and royalty benchmarks for adc her2 deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Seagen Licensing & Deal Activity
Seagen is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 4 deals over the past three years, Seagen ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Seagen include Solid Tumors (35 deals and trials), Hematological Malignancies (11 deals and trials), Oncology (3 deals and trials), and Neurology (2 deals and trials). In terms of modality, Seagen has shown particular interest in adc, adc her2, mab.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Seagen and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Seagen's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.